The recruitment activity within the AMYPAD Prognostic and Natural History Study (PNHS) has been less affected by the ongoing COVID-19 crisis in Q2 2021. The recruitment numbers have slightly improved compared to Q1 2021 and the number of scans significantly increased compared to Q1 2021. In total, at the end of Q2 2021, AMYPAD PNHS had 1,043 participants consented of which 909 have already undergone their amyloid PET scan.
At this moment, the PNHS has 17 active sites and 7 cohorts have been actively enrolling into the study. These are: EPAD-LCS, EMIF-AD, ALFA+, FACEHBI, FPACK, the UCL cohort and recently the Microbiota cohort. In May 2021 UNIGE managed to consent their first Microbiota participant into AMYPAD PNHS and now have consented 4 in total. In addition, two other cohorts have been confirmed to begin enrolment soon.
At the beginning of Q3 2021, the number of consents and scans will decrease as most sites have their summer period in which less participants will consent into AMYPAD PNHS and less scans will be performed as sites are closed. In September 2021, sites should be able to resume recruitment activity at full speed after the summer period and the number of consents and scans should start to increase once more.
Follow us on Twitter: @IMI_AMYPAD
Receive the latest news. Click here to subscribe!